Neurocrine to buy Soleno Therapeutics for $2.9 billion
Investing.com Gold reports: Neurocrine to buy Soleno Therapeutics for $2.9 billion. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Neurocrine to buy Soleno Therapeutics for $2.9 billion. Full body text was unavailable at ingest time, so this brief is based on headline context.